Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
| dc.rights.license | open | en_US |
| dc.contributor.author | COUSIN, Sophie | |
| dc.contributor.author | TOULMONDE, Maud | |
| dc.contributor.author | KIND, Michele | |
| dc.contributor.author | GUEGAN, Jean-Philippe | |
| dc.contributor.author | BESSEDE, Alban | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | CANTAREL, Coralie | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BELLERA, Carine | |
| dc.contributor.author | ITALIANO, Antoine | |
| dc.date.accessioned | 2023-02-15T09:10:22Z | |
| dc.date.available | 2023-02-15T09:10:22Z | |
| dc.date.issued | 2022-12-06 | |
| dc.identifier.issn | 2162-3619 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/171952 | |
| dc.description.abstractEn | Breast cancer is one the most common cause of cancer death in women worldwide. We report here the first phase II study investigating a virus genetically engineered for tumor-selective replication in patients with breast cancer. Ten patients were treated with a combination of low-dose oral cyclophosphamide and intra-venous JX-594, a thymidine kinase gene-inactivated oncolytic vaccinia virus engineered for the expression of transgenes encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF) and β-galactosidase. Best response as per RECIST criteria was stable disease for 2 patients and progressive disease for 8 patients. Median progression-free and overall survival were 1.6 months (95% CI: [1.1-1.9]) and 14.4 months (95% CI: [2.0 - NA]) respectively. High throughput analysis of sequential plasma samples revealed an upregulation of protein biomarkers reflecting immune induction such as IFN gamma. Whether the combination of JX-594 with an immune checkpoint inhibitor is associated with meaningful clinical activity is therefore worth to investigate. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Breast cancer | |
| dc.subject.en | Oncolytic virus | |
| dc.subject.en | JX-594 | |
| dc.title.en | Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer | |
| dc.title.alternative | Exp Hematol Oncol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1186/s40164-022-00338-2 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 36474303 | en_US |
| bordeaux.journal | Experimental Hematology & Oncology | en_US |
| bordeaux.volume | 11 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 1 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | EPICENE_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Institut National Du Cancer | en_US |
| bordeaux.identifier.funderID | Association pour la Recherche sur le Cancer | en_US |
| hal.identifier | hal-03989918 | |
| hal.version | 1 | |
| hal.date.transferred | 2023-02-15T09:10:24Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Experimental%20Hematology%20&%20Oncology&rft.date=2022-12-06&rft.volume=11&rft.issue=1&rft.eissn=2162-3619&rft.issn=2162-3619&rft.au=COUSIN,%20Sophie&TOULMONDE,%20Maud&KIND,%20Michele&GUEGAN,%20Jean-Philippe&BESSEDE,%20Alban&rft.genre=article |
